#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	14500	16S	1529	1529	100.0	16S.l15.c30.ctg.1	2330	758.4	1	SNP	n	C1184T	0	.	.	1184	1184	C	1566	1566	C	886	C	886	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	14500	16S	1529	1529	100.0	16S.l15.c30.ctg.1	2330	758.4	0	HET	.	.	.	G1158A,T	.	1158	1158	G	1540	1540	G	863	G,A,T	651,211,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	24312	23S	2890	2890	99.9	23S.l15.c17.ctg.1	3973	762.5	0	.	n	.	0	T695C	SNP	695	695	T	1205	1205	C	920	C,G	919,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	24312	23S	2890	2890	99.9	23S.l15.c17.ctg.1	3973	762.5	0	.	n	.	0	G1337A	SNP	1337	1337	G	1847	1847	A	924	A,T	923,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	24312	23S	2890	2890	99.9	23S.l15.c17.ctg.1	3973	762.5	0	.	n	.	0	T1971C	SNP	1971	1971	T	2481	2481	C	847	C	847	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	24312	23S	2890	2890	99.9	23S.l15.c17.ctg.1	3973	762.5	1	SNP	n	A2045G	0	.	.	2045	2045	A	2555	2555	A	709	A,G	708,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	24312	23S	2890	2890	99.9	23S.l15.c17.ctg.1	3973	762.5	1	SNP	n	C2597T	0	.	.	2597	2597	C	3107	3107	C	844	C,T,G,A	417,423,2,2	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	24312	23S	2890	2890	99.9	23S.l15.c17.ctg.1	3973	762.5	0	HET	.	.	.	G2872A,C	.	2872	2872	G	3382	3382	G	883	G,A,C	475,407,1	.	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	2158	folP	852	852	100.0	folP.l15.c4.ctg.1	1939	138.4	1	SNP	p	R228S	1	.	.	682	684	AGC	1207	1209	AGC	197;197;198	A;G;C	197;197;198	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5272	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3924	167.5	1	SNP	p	S91F	0	.	.	271	273	TCC	859	861	TCC	170;170;170	T;C;C,A	170;170;169,1	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5272	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3924	167.5	1	SNP	p	D95N	0	.	.	283	285	GAC	871	873	GAC	176;174;174	G;A;C	176;174;174	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5272	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3924	167.5	1	SNP	p	D95G	0	.	.	283	285	GAC	871	873	GAC	176;174;174	G;A;C	176;174;174	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_K_01388	mtrR.WHO_K_01388	1	1	27	1834	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1621	140.4	1	SNP	p	G45D	1	.	.	133	135	GAC	649	651	GAC	201;197;197	G;A;C	201;197;197	mtrR.WHO_K_01388:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	1012	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c17.ctg.1	1391	90.5	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4932	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3468	177.2	1	SNP	p	D86N	0	.	.	256	258	GAC	854	856	GAC	226;226;228	G;A,C;C,G,A	226;225,1;226,1,1	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4932	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3468	177.2	1	SNP	p	S87R	0	.	.	259	261	AGT	857	859	AGT	228;225;227	A;G;T	228;225;227	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4932	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3468	177.2	1	SNP	p	S87I	0	.	.	259	261	AGT	857	859	AGT	228;225;227	A;G;T	228;225;227	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4932	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3468	177.2	1	SNP	p	S87W	0	.	.	259	261	AGT	857	859	AGT	228;225;227	A;G;T	228;225;227	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4932	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3468	177.2	1	SNP	p	S88P	0	.	.	262	264	TCC	860	862	TCC	229;229;229	T,G;C,A;C	228,1;228,1;229	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4314	parE	1986	1986	100.0	parE.l15.c17.ctg.1	3015	178.2	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1707	1709	GGC	235;236;237	G,T;G;C	234,1;236;237	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	3890	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2913	166.5	1	SNP	p	A311V	0	.	.	931	933	GCA	1539	1541	GCA	239;238;237	G;C,G;A	239;237,1;237	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3890	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2913	166.5	1	SNP	p	I312M	0	.	.	934	936	ATC	1542	1544	ATC	239;235;235	A;T;C	239;235;235	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3890	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2913	166.5	1	SNP	p	V316P	0	.	.	946	948	GTG	1554	1556	GTG	241;243;242	G;T;G	241;243;242	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3890	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2913	166.5	1	SNP	p	V316T	0	.	.	946	948	GTG	1554	1556	GTG	241;243;242	G;T;G	241;243;242	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3890	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2913	166.5	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2058	2060	ACC	205;205;207	A;C,A;C	204;202,2;206	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3890	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2913	166.5	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2112	2114	GCG	185;183;184	G;C;G,T	185;183;183,1	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3890	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2913	166.5	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2112	2114	GCG	185;183;184	G;C;G,T	185;183;183,1	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3890	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2913	166.5	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2235	2237	GGC	218;220;219	G,C;G;C	217,1;220;219	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3890	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2913	166.5	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2244	2246	GGC	226;229;233	G,T;G;C	225,1;229;233	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3890	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2913	166.5	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2262	2264	CCG	250;248;246	C,G,T;C;G,T	246,3,1;248;245,1	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	27	5496	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3552	192.9	1	SNP	p	L421P	0	.	.	1261	1263	CTG	1886	1888	CTG	236;237;238	C,A;T;G	234,2;237;238	ponA.WHO_F_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2328	porA	1146	1146	99.83	porA.l15.c4.ctg.1	2285	126.8	0	.	p	.	0	M83fs	FSHIFT	247	247	A	867	867	C	186	C	186	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2474	porB1b	1041	1041	96.47	porB1b.l15.c17.ctg.1	1862	165.1	0	.	p	.	0	E48G	NONSYN	142	144	GAA	727	729	GGA	208;208;212	G;G;A	208;208;212	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2474	porB1b	1041	1041	96.47	porB1b.l15.c17.ctg.1	1862	165.1	0	.	p	.	0	V75I	NONSYN	223	225	GTT	808	810	ATT	223;222;223	A;T;T,G	223;222;222,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2474	porB1b	1041	1041	96.47	porB1b.l15.c17.ctg.1	1862	165.1	0	.	p	.	0	T89S	NONSYN	265	267	ACC	850	852	AGC	224;222;223	A;G;C	224;222;223	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2474	porB1b	1041	1041	96.47	porB1b.l15.c17.ctg.1	1862	165.1	0	.	p	.	0	V98I	NONSYN	292	294	GTC	877	879	ATC	196;197;199	A,T;T,G;C,A	195,1;195,2;198,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2474	porB1b	1041	1041	96.47	porB1b.l15.c17.ctg.1	1862	165.1	0	.	p	.	0	.	MULTIPLE	358	359	AA	942	943	CG	190;190	C,G;G	189,1;190	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2474	porB1b	1041	1041	96.47	porB1b.l15.c17.ctg.1	1862	165.1	0	.	p	.	0	.	MULTIPLE	361	362	GA	945	947	CAG	185;184;181	C;A,T;G	185;183,1;181	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2474	porB1b	1041	1041	96.47	porB1b.l15.c17.ctg.1	1862	165.1	0	.	p	.	0	N122K	NONSYN	364	366	AAC	949	951	AAA	182;182;184	A;A;A	182;182;184	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2474	porB1b	1041	1041	96.47	porB1b.l15.c17.ctg.1	1862	165.1	0	.	p	.	0	F131Y	NONSYN	391	393	TTT	976	978	TAT	173;171;173	T;A,T,G;T	173;169,1,1;173	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2474	porB1b	1041	1041	96.47	porB1b.l15.c17.ctg.1	1862	165.1	0	.	p	.	0	N134E	NONSYN	400	402	AAT	985	987	GAG	177;177;177	G,A;A;G,T	176,1;177;176,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2474	porB1b	1041	1041	96.47	porB1b.l15.c17.ctg.1	1862	165.1	0	.	p	.	0	V135L	NONSYN	403	405	GTG	988	990	CTT	177;180;180	C,G;T,G;T,G	176,1;179,1;179,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2474	porB1b	1041	1041	96.47	porB1b.l15.c17.ctg.1	1862	165.1	0	.	p	.	0	G140K	NONSYN	418	420	GGA	1003	1005	AAA	193;193;193	A,G;A,G,C;A	192,1;191,1,1;193	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2474	porB1b	1041	1041	96.47	porB1b.l15.c17.ctg.1	1862	165.1	0	.	p	.	0	K143E	NONSYN	427	429	AAA	1012	1014	GAA	191;192;195	G;A,T,C;A	191;190,1,1;195	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2474	porB1b	1041	1041	96.47	porB1b.l15.c17.ctg.1	1862	165.1	0	.	p	.	0	V151A	NONSYN	451	453	GTA	1036	1038	GCA	204;204;202	G,T;C;A	203,1;204;202	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2474	porB1b	1041	1041	96.47	porB1b.l15.c17.ctg.1	1862	165.1	0	.	p	.	0	T213S	NONSYN	637	639	ACA	1222	1224	TCA	256;258;263	T;C,A;A	256;257,1;263	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2474	porB1b	1041	1041	96.47	porB1b.l15.c17.ctg.1	1862	165.1	0	.	p	.	0	G253Q	NONSYN	757	759	GGA	1342	1344	CAA	175;174;171	C;A;A	175;174;171	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2474	porB1b	1041	1041	96.47	porB1b.l15.c17.ctg.1	1862	165.1	0	.	p	.	0	.	INDELS	760	761	AC	1346	1349	ATCG	169;165;161;157	A;T,A;C;G	169;164,1;161;157	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2474	porB1b	1041	1041	96.47	porB1b.l15.c17.ctg.1	1862	165.1	0	.	p	.	0	.	INDELS	763	764	TG	1352	1355	TAGT	150;148;149;151	T;A;G;T	150;148;149;151	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2474	porB1b	1041	1041	96.47	porB1b.l15.c17.ctg.1	1862	165.1	0	.	p	.	0	A257D	NONSYN	769	771	GCT	1360	1362	GAT	150;150;152	G;A,C;T	150;149,1;152	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2474	porB1b	1041	1041	96.47	porB1b.l15.c17.ctg.1	1862	165.1	0	.	p	.	0	D293S	NONSYN	877	879	GAT	1468	1470	AGT	237;238;241	A;G;T,C	237;238;240,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2474	porB1b	1041	1041	96.47	porB1b.l15.c17.ctg.1	1862	165.1	0	.	p	.	0	N295D	NONSYN	883	885	AAC	1474	1476	GAC	248;251;254	G,C;A;C	247,1;251;254	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2474	porB1b	1041	1041	96.47	porB1b.l15.c17.ctg.1	1862	165.1	0	.	p	.	0	H296Y	NONSYN	886	888	CAC	1477	1479	TAC	256;256;260	T;A;C	256;256;260	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2474	porB1b	1041	1041	96.47	porB1b.l15.c17.ctg.1	1862	165.1	1	SNP	p	G120K	1	.	.	358	360	AAG	942	944	CGG	190;190;188	C,G;G;G,C	189,1;190;187,1	porB1b.WHO_M_02204c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2474	porB1b	1041	1041	96.47	porB1b.l15.c17.ctg.1	1862	165.1	1	SNP	p	A121D	1	.	.	361	363	GAC	945	948	CGC	185;181;182	C;G;C	185;181;182	porB1b.WHO_M_02204c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2474	porB1b	1041	1041	96.47	porB1b.l15.c17.ctg.1	1862	165.1	1	SNP	p	D121N	0	.	.	361	363	GAC	945	948	CGC	185;181;182	C;G;C	185;181;182	porB1b.WHO_M_02204c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	9412	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	5231	224.3	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2210	2212	AAT	226;224;228	A;A;T	226;224;228	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1302	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1499	108.5	1	SNP	p	V57M	1	.	.	169	171	ATG	783	785	ATG	242;240;238	A;T;G	242;240;238	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
